文章：

急性髓系白血病的双特异性抗体靶点

Acute myeloid leukemia targets for bispecific antibodies

原文发布日期：2017-02-03

DOI: 10.1038/bcj.2017.2

类型: Review

开放获取: 是

英文摘要：

Despite substantial gains in our understanding of the genomics of acute myelogenous leukemia (AML), patient survival remains unsatisfactory especially among the older age group. T cell-based therapy of lymphoblastic leukemia is rapidly advancing; however, its application in AML is still lagging behind. Bispecific antibodies can redirect polyclonal effector cells to engage chosen targets on leukemia blasts. When the effector cells are natural-killer cells, both antibody-dependent and antibody-independent mechanisms could be exploited. When the effectors are T cells, direct tumor cytotoxicity can be engaged followed by a potential vaccination effect. In this review, we summarize the AML-associated tumor targets and the bispecific antibodies that have been studied. The potentials and limitations of each of these systems will be discussed.

摘要翻译： 

尽管我们在急性髓系白血病（AML）基因组学方面的认识已取得重大进展，但患者的生存率仍不理想，尤其是在老年群体中。基于T细胞的淋巴细胞白血病治疗进展迅速，然而其在AML中的应用仍相对滞后。双特异性抗体可以引导多克隆效应细胞作用于白血病原始细胞上的特定靶点。当效应细胞为自然杀伤细胞时，抗体依赖性和非抗体依赖性机制均可被利用。当效应细胞为T细胞时，可直接激活肿瘤细胞毒性作用，并可能产生后续的疫苗接种效应。本综述总结了与AML相关的肿瘤靶点及已研究的双特异性抗体，并将探讨这些治疗体系的潜力与局限性。

原文链接：

Acute myeloid leukemia targets for bispecific antibodies